Back to results

Application of state-of-the-art Raman Chemical Imaging and Chemometrics to accelerate and improve patent prostate biopsy assessment for cancer

Currently pathologists depend upon staining processes to illuminate important features of a biopsy to increase the clarity of features (e.g. cell nuclei and cytoplasm). Unfortunately the staining process is inconsistent and can be unreliable. Furthermore creating the stains is expensive, laborious and slow. Critically, the staining process doesn’t eliminate the need for a pathologist to examine biopsies at high magnification. This means that for a rigorous biopsy examination an unfeasibly long time would be needed by the pathologist for a full examination. This project investigates the potential of a novel emerging technology, Raman Chemical Imaging, combined with existing methodologies (i.e. staining, digital imaging, historical patient data) using multivariate data analysis (chemometrics), to objectively assess prostate tissue (Figure 1). Raman spectroscopy enables nondestructive analysis of the molecular composition of tissue based on its interaction with light and its potential for identification of various cancer types has been demonstrated. Raman Chemical Imaging combines conventional Raman Spectroscopy with spatial mapping to provide a detailed chemical map over the surface of a sample, thus generating highly detailed chemical images of the prostate tissue that contain biochemical information imperceptible by conventional methods. We propose merging Raman datasets with existing digital pathology and patient medical histories to generate predictive models of patient outcomes from pre-radical prostatectomy data. A variety of chemometric approaches will be implemented to develop image fusion, classification and predictive models. With the ability to collect data that can objectively, rapidly, reproducibly and repeatably classify tissue regions, grading protocols will be less reliant on subjective, inconsistent datasets. Thus more robust and more accurate predictions of likely patient outcomes and treatment recommendations can be made at an earlier date, thus delivering better patient health outcomes and better use of limited health resources.